Fintel reports that on February 6, 2025, William Blair initiated coverage of Mersana Therapeutics (NasdaqGS:MRSN) with a ...

JP Morgan analyst Samik Chatterjee initiated coverage on Jamf Holding Corp. JAMF with an Overweight rating and announced a ...

William Blair initiated coverage on Mersana Therapeutics, Inc. (NASDAQ:MRSN) with an Outperform rating. The firm's analyst cited the company's potential in the antibody-drug conjugates (ADCs) market ...

William Blair analyst Andy Hsieh last night initiated coverage of Mersana Therapeutics (MRSN) with an Outperform rating. The firm believes ...

CAMBRIDGE, Mass., Jan. 30, 2025 (GLOBE NEWSWIRE) -- (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on ...

Shares of Mersana Therapeutics, Inc. (NASDAQ:MRSN – Get Free Report) have been given a consensus rating of “Moderate Buy” by the eight analysts that are presently covering the company, Ratings reports ...

CAMBRIDGE, MA — On January 15, Ashish Mandelia, Vice President and Chief Accounting Officer at Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company with a market ...

CAMBRIDGE, MA—Mersana Therapeutics, Inc. (NASDAQ:MRSN), currently trading near its 52-week low of $0.56, recently disclosed that its President and CEO, Martin H. Huber Jr., executed a stock sale ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...